38116-61-9

Basic information

• Product Name: 2-Hydroxy-6-methylpyridine-3-carboxylic acid
• Synonyms: 3-CARBOXY-6-METHYL-2-PYRIDINOL;3-CARBOXY-6-METHYL-2-PYRIDONE;3-CARBOXY-2-HYDROXY-6-METHYLPYRIDINE;2-HYDROXY-6-METHYLPYRIDINE-3-CARBOXYLIC ACID;3-Carboxy-6-methyl-2-pyridone~2-Hydroxy-6-methylpyridine-3-carboxylic acid;2-Hydroxy-6-methylnicotinic acid, 98+%;1,2-Dihydro-6-methyl-2-oxonicotinic acid;3-Pyridinecarboxylic acid, 1,2-dihydro-6-methyl-2-oxo-
• CAS NO: 38116-61-9
• Molecular Formula: C₇H₇NO₃
• Molecular Weight: 153.14
• EINECS: 253-784-3
• Product Categories: Pyridines, Pyrimidines, Purines and Pteredines;Carboxylic Acids;Pyridines;Carboxylic Acids;C7 and C8;Heterocyclic Building Blocks
• Mol File: 38116-61-9.mol
• Article Data: 11

Chemical Properties

• Melting Point: 233-235 °C(lit.)
• Boiling Point: 276.03°C (rough estimate)
• Flash Point: 204.4 °C
• Appearance: light yellow to light orange crystalline powder,. crystals or needles
• Density: 1.3585 (rough estimate)
• Vapor Pressure: 5E-08mmHg at 25°C
• Refractive Index: 1.5500 (estimate)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 2.54±0.20(Predicted)
• BRN: 129164
• CAS DataBase Reference: 2-Hydroxy-6-methylpyridine-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Hydroxy-6-methylpyridine-3-carboxylic acid(38116-61-9)
• EPA Substance Registry System: 2-Hydroxy-6-methylpyridine-3-carboxylic acid(38116-61-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38-36
• Safety Statements: 36/37/39-26-22
• WGK Germany: 3
• Hazardous Substances Data: 38116-61-9(Hazardous Substances Data)

Usage

Chemical Properties

light yellow to light orange crystalline powder,

InChI:InChI=1/C7H7NO3/c1-4-2-3-5(7(10)11)6(9)8-4/h2-3H,1H3,(H,8,9)(H,10,11)/p-1

Upstream product

• 4241-27-4 1,2-dihydro-6-methyl-2-oxo-3-pyridinecarbonitrile 
• 3222-47-7 6-methylnicotinic acid 
• 4241-27-4 2-hydroxy-6-methylnicotinonitrile 

Downstream Products

• 51146-06-6 methyl-2-hydroxy-6-methylpyridine-3-carboxylate 
• 147269-61-2 (2-hydroxy-6-methylpyridin-3-yl)carbamic acid benzyl ester 
• 195315-30-1 N-((S)-1-Carbamimidoyl-2-ethoxy-piperidin-3-yl)-2-(6-methyl-2-oxo-3-phenylmethanesulfonylamino-2H-pyridin-1-yl)-acetamide 
• 193278-22-7 [3-[(benzylsulfonyl)amino]-6-methyl-2-oxo-1,2-dihydropyridyl]acetyl-Ng-nitro-L-argininal ethyl cyclol 
• 147269-61-2 benzyl N-(6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)carbamate 
• 117449-75-9 5-chloro-2-hydroxy-6-methyl-3-pyridinecarboxylic acid 
• 39853-81-1 2-chloro-6-methyl-nicotinic acid chloride 
• 51146-04-4 ethyl 2-hydroxy-6-methylpyridine-3-carboxylate 
• 934361-39-4 methyl 5-chloro-2-hydroxy-6-methylpyridine-3-carboxylate 

Relevant articles and documents

A tautomeric ligand enables directed C-H hydroxylation with molecular oxygen

Hydroxylation of aryl carbon-hydrogen bonds with transition metal catalysts has proven challenging when oxygen is used as the oxidant. Here, we report a palladium complex bearing a bidentate pyridine/ pyridone ligand that efficiently catalyzes this reaction at ring positions adjacent to carboxylic acids. Infrared, x-ray, and computational analysis support a possible role of ligand tautomerization from monoanionic (L,X) to neutral (L,L) coordination in the catalytic cycle of aerobic carbon-hydrogen hydroxylation reaction. The conventional site selectivity dictated by heterocycles is overturned by this catalyst, thus allowing late-stage modification of compounds of pharmaceutical interest at previously inaccessible sites.

Aromatic heterocyclic derivatives as enzyme inhibitors

The present invention discloses peptide aldehydes which are potent and specific inhibitors of thrombin, their pharmaceutically acceptable salts, pharmaceutically acceptable compositions thereof, and methods of using them as therapeutic agents for disease states in mammals characterized by abnormal thrombosis.

AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS

The present invention discloses peptide aldehydes which are potent and specific inhibitors of thrombin, their pharmaceutically acceptable salts, pharmaceutically acceptable compositions thereof, and methods of using them as therapeutic agents for disease states in mammals characterized by abnormal thrombosis.